VivoSeq
Other

Acute Otitis Media

27

Pipeline Programs↗

0

Active Trials↗

17

Companies Involved↗

Acute otitis media is an emerging landscape with 27 programs across 17 companies. The most active players are Currax Pharmaceuticals, Iterum Therapeutics, International Limited, Arbor Pharmaceuticals, Inc.. 8 therapies are approved with 14 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

89/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Currax Pharmaceuticals

2 programs

Phase 2I

Iterum Therapeutics, International Limited

1 program

Phase 2A

Arbor Pharmaceuticals, Inc.

2 programs

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3Sanofi logo

Sanofi

1 program

Phase 3Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

97%

Small molecule

31 of 32 classified programs — the dominant modality here.

3%ALL OTHERSVaccine13%

Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 100% of 38 pipeline programs.

Analysis

Trial Status

38

clinical trials

Completed33 · 87%
Terminated4 · 11%
Unknown status1 · 3%

Clinical Trials

Trial Activity

38 trials

Japanese Study Evaluating the Effects of Telithromycin in Children With Acute Otitis Media
Completed·Sanofi logoSanofi·Phase 3·NCT00638534·56 enrolled
Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media
Completed·Pfizer logoPfizer·N/A·NCT00195611·3,293 enrolled
Amoxicillin-clavulanate in Treating Acute Otitis Media Evaluated by Daily Tympanometry
Completed·UUniversity of Oulu·Phase 3·NCT01244581·84 enrolled
Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India
Completed·GSK logoGSK·Phase 4·NCT04600752·310 enrolled
Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence
Completed·UUniversity Hospital Tuebingen·Phase 3·NCT02345447·296 enrolled
A Trial to Evaluate Faropenem Medoxomil in the Treatment of Acute Otitis Media
Completed·RReplidyne·Phase 2·NCT00276042·328 enrolled
Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora
Completed·AAlcon Research·N/A·NCT01027494·318 enrolled
Efficacy Trial of Two Pneumococcal Conjugate Vaccines (PncCRM and PncOMPC) for Prevention of Acute Otitis Media Due to Vaccine Serotypes
Completed·FFinnish Institute for Health and Welfare·Phase 3·NCT00378417·3,075 enrolled
Zmax Pediatric Vs Adult Concentration For The Treatment Of Acute Otitis Media
Completed·Pfizer logoPfizer·Phase 3·NCT00360100·120 enrolled
Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media
Completed·CCurrax Pharmaceuticals·Phase 2·NCT02037893·112 enrolled
Study to Assess the Safety and Efficacy of Benzocaine for Pain Relief in Children Presenting With Acute Otitis Media
Completed·OOtic Therapy, LLC·Phase 2·NCT02092454·65 enrolled
A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media
Completed·AAbbott·Phase 4·NCT00644943·425 enrolled
Pharmacokinetics Of Azithromycin Immediate Release And Extended Release Formulation In Kids With Acute Otitis Media
Completed·Pfizer logoPfizer·Phase 2·NCT00796224·38 enrolled
Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media
Completed·AArbor Pharmaceuticals, Inc.·Phase 3·NCT02044341·304 enrolled
COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine
Completed·GSK logoGSK·Phase 3·NCT00466947·23,802 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)